Review
Pathology
Sofia Rodriguez Murua, Mauricio F. Farez, Francisco J. Quintana
Summary: Multiple sclerosis is a chronic disease affecting the central nervous system, characterized by immune dysregulation and resulting in demyelination, neuronal damage, and degeneration. Genetic and environmental factors are believed to play a role in the onset and progression of this disease.
ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE
(2022)
Article
Clinical Neurology
Kevin Bigaut, Laurent Kremer, Thibaut Fabacher, Guido Ahle, Mathilde Goudot, Marie Fleury, Claude Gaultier, Sylvie Courtois, Nicolas Collongues, Jerome de Seze
Summary: This study compared the effectiveness of ocrelizumab and fingolimod after natalizumab cessation. The results showed that ocrelizumab had a significantly lower relapse rate at 1 year compared to fingolimod.
JOURNAL OF NEUROLOGY
(2022)
Review
Medicine, General & Internal
Athina-Maria Aloizou, Vasileios Siokas, Georgia Pateraki, Ioannis Liampas, Christos Bakirtzis, Zisis Tsouris, George Lazopoulos, Daniela Calina, Anca Oana Docea, Aristidis Tsatsakis, Dimitrios P. Bogdanos, Efthimios Dardiotis
Summary: Numerous studies have explored the potential of using multiple sclerosis disease-modifying drugs in the setting of ischemic stroke, yielding mostly positive results in animal studies. However, concerns on safety and other issues need to be addressed before implementing these drugs in clinical practice.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Clinical Neurology
S. Guerrieri, S. Lazzarin, C. Zanetta, A. Nozzolillo, M. Filippi, L. Moiola
Summary: This study found variable antibody production in multiple sclerosis patients receiving fingolimod or ocrelizumab treatments after receiving a complete SARS-CoV-2 vaccination course. Clinical features did not show a clear correlation with serological response. There is currently insufficient data to recommend against COVID-19 vaccination in these patients.
JOURNAL OF NEUROLOGY
(2022)
Article
Clinical Neurology
Jamie K. Wong, Jerry Lin, Nathan J. Kung, Alexandra L. Tse, Serena J. E. Shimshak, Anna K. Roselle, Francesca M. Cali, Jessie Huang, Joseph M. Beaty, Taylor M. Shue, Saud A. Sadiq
Summary: Multiple sclerosis can present as relapsing-remitting or progressive forms. It is unclear whether these forms represent the same disease or distinct entities with similar pathological features. This study provides evidence that primary progressive multiple sclerosis is characterized by a unique capacity of cerebrospinal fluid (CSF) to induce motor disability and spinal cord pathology, which can be attenuated by removing immunoglobulin G from the CSF. Injection of recombinant antibodies derived from primary progressive multiple sclerosis CSF reproduces the pathology, suggesting an antibody-mediated and distinct pathogenic mechanism for this form of the disease. These findings have important implications for developing targeted therapies for primary progressive multiple sclerosis patients.
Article
Cell Biology
Leoni Rolfes, Steffen Pfeuffer, Jelena Skuljec, Xia He, Chuanxin Su, Sinem-Hilal Oezalp, Marc Pawlitzki, Tobias Ruck, Melanie Korsen, Konstanze Kleinschnitz, Derya Aslan, Tim Hagenacker, Christoph Kleinschnitz, Sven G. Meuth, Refik Pul
Summary: Cladribine-treated MS patients can mount an adequate immune response to influenza independently of treatment duration and time interval to the last cladribine administration. The antibody response against influenza A was comparable between cladribine-treated patients and controls, while the response against influenza B was lower in the cladribine cohort. The increase in geometric mean titers was also lower in the cladribine group compared to controls, but titers increased in both groups for all strains.
Article
Cardiac & Cardiovascular Systems
Zaki Al-Yafeai, Alexander Carvajal-Gonzalez, Hamzah Abduljabar, Muhammed Arvas, Shaan Patel, Neev Patel
Summary: This study comprehensively evaluated the cardiovascular complications of the newly FDA-approved anti-multiple sclerosis (MS) modifying therapies. CD20 and CD25 inhibitors were significantly associated with cardiovascular adverse events, while S1PR agonists showed fewer cardiac complications. These findings are important for personalized prescribing of MS agents based on the patient's cardiovascular profile.
INTERNATIONAL JOURNAL OF CARDIOLOGY
(2022)
Article
Health Care Sciences & Services
Laura Ferre, Ferdinando Clarelli, Beatrice Pignolet, Elisabetta Mascia, Marco Frasca, Silvia Santoro, Melissa Sorosina, Florence Bucciarelli, Lucia Moiola, Vittorio Martinelli, Giancarlo Comi, Roland Liblau, Massimo Filippi, Giorgio Valentini, Federica Esposito
Summary: In this study, machine learning methods were used to predict the response of multiple sclerosis patients to fingolimod based on clinical and genetic features. Two patient cohorts from Italy and France were analyzed, and separate predictive models with genetic features only and combined clinical-genetic features were obtained. The results showed that machine learning methods can provide accurate prediction of fingolimod response.
JOURNAL OF PERSONALIZED MEDICINE
(2023)
Article
Pharmacology & Pharmacy
Sekhar Surapaneni, Usha Yerramilli, April Bai, Deepak Dalvie, Jennifer Brooks, Xiaomin Wang, Julie Selkirk, Yingzhuo Grace Yan, Peijin Zhang, Richard Hargreaves, Gondi Kumar, Maria Palmisano, Jonathan Q. Tran
Summary: Absorption, metabolism, and excretion of ozanimod in humans were characterized, and the enzymes involved in complex metabolism were elucidated. Disproportionate metabolites were identified, and the activity of these metabolites was determined.
DRUG METABOLISM AND DISPOSITION
(2021)
Letter
Clinical Neurology
Fernando X. Cuascut, Samir Alkabie, George J. Hutton
Summary: Fingolimod is an oral medication commonly used to treat multiple sclerosis by sequestering certain subsets of lymphocytes. However, post-discontinuation may lead to opportunistic infections like cryptococcal meningitis and IRIS. Surveillance and risk mitigation strategies are recommended.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2021)
Article
Clinical Neurology
Johannes Lorscheider, Pascal Benkert, Carmen Lienert, Peter Haenni, Tobias Derfuss, Jens Kuhle, Ludwig Kappos, Oezguer Yaldizli
Summary: In a real-world setting, dimethyl fumarate and fingolimod demonstrate comparable effectiveness in reducing relapses and disability worsening in patients with RRMS. Findings from this study suggest that there is no significant difference in efficacy between the two treatment options, regardless of whether patients are treatment-naive or switching from another DMT.
JOURNAL OF NEUROLOGY
(2021)
Article
Cell Biology
Diana Ferraro, Sara De Biasi, Anna Maria Simone, Riccardo Orlandi, Milena Nasi, Francesca Vitetta, Marcello Pinti, Marco Fogliani, Stefano Meletti, Andrea Cossarizza, Patrizia Sola
Summary: The study found that the proportions of Tregs and iNKT cells in the immunoregulatory cell networks changed in patients with Multiple Sclerosis, and FTY treatment may benefit patients by increasing cells with immunomodulatory potential.
Article
Biochemistry & Molecular Biology
Andrea Olmos-Ortiz, Mayra Hernandez-Perez, Pilar Flores-Espinosa, Gabriela Sedano, Addy Cecilia Helguera-Repetto, Oscar Villavicencio-Carrisoza, Maria Yolotzin Valdespino-Vazquez, Arturo Flores-Pliego, Claudine Irles, Bruno Rivas-Santiago, Elsa Romelia Moreno-Verduzco, Lorenza Diaz, Veronica Zaga-Clavellina
Summary: Infectious processes in the uterine cavity can compromise the maternal-fetal unit and increase the risk of preterm birth and premature rupture of membranes. This study aimed to characterize the synthesis, activity, and distribution of antimicrobial peptides (AMPs) produced by fetal membranes in response to a choriodecidual Escherichia coli infection. The results showed a temporal- and tissue-specific pattern of AMP synthesis, but the membranes were unable to contain bacterial growth and migration despite the production of AMPs, increasing the risk of preterm birth and premature rupture of membranes.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Biochemistry & Molecular Biology
Federica Murgia, Florianna Giagnoni, Lorena Lorefice, Paola Caria, Tinuccia Dettori, Maurizio N. N. D'Alterio, Stefano Angioni, Aran J. J. Hendren, Pierluigi Caboni, Monica Pibiri, Giovanni Monni, Eleonora Cocco, Luigi Atzori
Summary: Sex hormones are correlated with the clinical activity of multiple sclerosis. Estrogens and progesterone may have a neuroprotective effect in MS, supporting further research on their therapeutic uses.
Article
Clinical Neurology
Irene Schiavetti, Matilde Inglese, Jessica Frau, Elisabetta Signoriello, Francesca Caleri, Maria Laura Stromillo, Maria Teresa Ferro, Maria Teresa Rilla, Ilaria Gandoglia, Paola Gazzola, Giampaolo Brichetto, Livia Pasquali, Luigi Grimaldi, Monica Ulivelli, Fabiana Marinelli, Susanna Cordera, Marinella Clerico, Antonella Conte, Marco Salvetti, Mario Alberto Battaglia, Diego Franciotta, Antonio Uccelli, Maria Pia Sormani
Summary: This study evaluates the differences in immune response after a third vaccine dose in patients with multiple sclerosis (pwMS). The results show that patients on anti-CD20 drugs rituximab and ocrelizumab had a lower increase in antibody levels compared to patients treated with other drugs, while patients on fingolimod showed a higher increase. All pwMS increased their serum antibody levels after the third vaccine dose.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Meeting Abstract
Clinical Neurology
A. Sugai, T. Kato, T. Ishihara, O. Osamu
JOURNAL OF THE NEUROLOGICAL SCIENCES
(2017)
Meeting Abstract
Clinical Neurology
T. Ishihara, S. Toyoda, A. Koyama, M. Tada, N. Atsuta, R. Nakamura, G. Tohnai, J. Sone, Y. Izumi, R. Kaji, M. Morita, A. Taniguchi, A. Kakita, G. Sobue, M. Nishizawa, O. Onodera
JOURNAL OF THE NEUROLOGICAL SCIENCES
(2017)
Article
Clinical Neurology
Joana Machado-Santos, Etsuji Saji, Anna R. Troescher, Manuela Paunovic, Roland Liblau, Galina Gabriely, Christian G. Bien, Jan Bauer, Hans Lassmann
Article
Biochemistry & Molecular Biology
Natsumi Saito, Tomohiko Ishihara, Kensaku Kasuga, Mana Nishida, Takanobu Ishiguro, Hiroaki Nozaki, Takayoshi Shimohata, Osamu Onodera, Masatoyo Nishizawa
Article
Neurosciences
Akihiro Sugai, Taisuke Kato, Akihide Koyama, Yuka Koike, Sou Kasahara, Takuya Konno, Tomohiko Ishihara, Osamu Onodera
FRONTIERS IN NEUROSCIENCE
(2018)
Article
Neurosciences
Akihiro Sugai, Taisuke Kato, Akihide Koyama, Yuka Koike, Takuya Konno, Tomohiko Ishihara, Osamu Onodera
NEUROBIOLOGY OF DISEASE
(2019)
Article
Neurosciences
Fumiaki Mori, Mari Tada, Tomoya Kon, Yasuo Miki, Kunikazu Tanji, Hidekachi Kurotaki, Masahiko Tomiyama, Tomohiko Ishihara, Osamu Onodera, Akiyoshi Kakita, Koichi Wakabayashi
ACTA NEUROPATHOLOGICA COMMUNICATIONS
(2019)
Article
Clinical Neurology
Shinji Ohara, Taka-aki Miyahira, Kenya Oguchi, Yo-ichi Takei, Fumihiro Yanagimura, Izumi Kawachi, Kiyomitsu Oyanagi, Akiyoshi Kakita
Article
Biology
Ryoichi Nakamura, Kazuharu Misawa, Genki Tohnai, Masahiro Nakatochi, Sho Furuhashi, Naoki Atsuta, Naoki Hayashi, Daichi Yokoi, Hazuki Watanabe, Hirohisa Watanabe, Masahisa Katsuno, Yuishin Izumi, Kazuaki Kanai, Nobutaka Hattori, Mitsuya Morita, Akira Taniguchi, Osamu Kano, Masaya Oda, Kazumoto Shibuya, Satoshi Kuwabara, Naoki Suzuki, Masashi Aoki, Yasuyuki Ohta, Toru Yamashita, Koji Abe, Rina Hashimoto, Ikuko Aiba, Koichi Okamoto, Kouichi Mizoguchi, Kazuko Hasegawa, Yohei Okada, Tomohiko Ishihara, Osamu Onodera, Kenji Nakashima, Ryuji Kaji, Yoichiro Kamatani, Shiro Ikegawa, Yukihide Momozawa, Michiaki Kubo, Noriko Ishida, Naoko Minegishi, Masao Nagasaki, Gen Sobue
COMMUNICATIONS BIOLOGY
(2020)
Letter
Clinical Neurology
Makoto Sainouchi, Hidetomo Tanaka, Hiroshi Shimizu, Takuya Mashima, Takao Fukushima, Yuya Hatano, Tomohiko Ishihara, Kunihiko Makino, Osamu Onodera, Akiyoshi Kakita
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2021)
Letter
Neurosciences
Makoto Sainouchi, Yuya Hatano, Mari Tada, Tomohiko Ishihara, Shoichiro Ando, Taisuke Kato, Jun Tokunaga, Gaku Ito, Hiroaki Miyahara, Yasuko Toyoshima, Akio Yokoseki, Tetsutaro Ozawa, Kohei Akazawa, Osamu Onodera, Akiyoshi Kakita
ACTA NEUROPATHOLOGICA COMMUNICATIONS
(2021)
Article
Biology
Yuka Koike, Akihiro Sugai, Norikazu Hara, Junko Ito, Akio Yokoseki, Tomohiko Ishihara, Takuma Yamagishi, Shintaro Tsuboguchi, Mari Tada, Takeshi Ikeuchi, Akiyoshi Kakita, Osamu Onodera
Summary: The research showed that DNA demethylation in the autoregulatory region of TARDBP 3 ' UTR, encoding TDP-43, increases with age in ALS patients, which may be indicative of a role for dysregulation of TDP-43 autoregulation in ALS pathology.
COMMUNICATIONS BIOLOGY
(2021)
Article
Neurosciences
Tomohiko Ishihara, Akihide Koyama, Yuya Hatano, Ryoko Takeuchi, Yuka Koike, Taisuke Kato, Mari Tada, Akiyoshi Kakita, Osamu Onodera
Summary: In this study, the expression of HERV-K mRNA in the motor cortex and spinal cord of Japanese ALS patients and controls was analyzed. The results showed no significant increase in HERV-K expression in ALS-affected tissues, suggesting the association between ALS and HERV-K remains questionable.
NEUROSCIENCE RESEARCH
(2022)
Article
Biochemical Research Methods
Yuya Hatano, Tomohiko Ishihara, Osamu Onodera
Summary: Researchers have developed a technique called MOVA that uses positional information from AlphaFold2 to predict the pathogenicity of rare variants in ALS causative genes. The method shows good predictive accuracy in ALS-related genes and can be used in combination with other prediction methods.
BMC BIOINFORMATICS
(2023)
Letter
Clinical Neurology
Masahiro Uemura, Sho Kitahara, Taisuke Kato, Hiroaki Nozaki, Shoichiro Ando, Tomohiko Ishihara, Osamu Onodera
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY
(2023)
